Aerobic capacity in late adolescents infected with HIV and controls

Pediatric Rehabilitation

Volumn 5, Issue 3, 2002, Pages 161-169

  Cade, W Todd ^a   Peralta, Ligia ^a   Keyser, Randall E ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescents; Disability; Exercise; HIV; Oxygen consumption

Indexed keywords

CARBON DIOXIDE;

ADOLESCENT; AEROBIC CAPACITY; AGE DISTRIBUTION; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAM; EXERCISE TEST; FEMALE; HEMATOCRIT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; OXYGEN CONSUMPTION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SEX DIFFERENCE; SPIROMETRY; TREADMILL; VIRUS LOAD;

ADOLESCENT; BODY MASS INDEX; CARDIOVASCULAR DECONDITIONING; ELECTROCARDIOGRAPHY; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART RATE; HIV INFECTIONS; HUMANS; MALE; OXYGEN CONSUMPTION; RESPIRATION; SPIROMETRY; VIRAL LOAD;

EID: 80052102002     PISSN: 13638491     EISSN: None     Source Type: Journal    
DOI: 10.1080/1363849021000039362     Document Type: Article

References (58)

1. JOHNSON, J. E., ANDERS, G. T., BLANTON, H. M., et al.: Exercise dysfunction in patients seropositive for the human immunodeficiency virus. American Review of Respiratory Disease, 141: 618-622, 1990.
2. MACARTHUR, R. D., LEVINE, S. D. and BIRK, T. J.: Supervised exercise training improves cardiopulmonary fitness in HIV-infected persons. Medicine and Science in Sports and Exercise, 25: 684-688, 1993.
3. POTHOFF G., WASSERMANN K. and OSTMANN H.: Impairment of exercise capacity in various groups of HIV-infected patients. Respiration, 61: 80-85, 1994.
4. STRINGER, W. W., BEREZOVSKAYA, M., O'BRIEN, W. A., et al.: The effect of exercise training on aerobic fitness, immune indices, and quality of life in HIV+ patients. Medicine and Science in Sports and Exercise, 30: 11-16, 1998.
5. PERNA, F. M., LAPERRIERE, A., KLIMAS, N., et al.: Cardiopulmonary and CD4 cell changes in response to exercise training in early symptomatic HIV infection. Medicine and Science in Sports and Exercise, 31: 973-979, 1999.
6. KEYSER, R. E., PERALTA, L., CADE, W. T., et al.: Functional aerobic impairment in adolescents seropositive for HIV: a quasiexperimental analysis. Archives of Physical Medicine and Rehabilitation, 81: 1479-1484, 2000.
7. FRANKLIN, B. A. and TIMMIS, G. C.: Fundamentals of exercise physiology: implications for exercise testing and prescription. In: B. A. Franklin and G. C. Timmis (editors) Exercise in Modern Medicine. (Williams and Wilkins: Baltimore), p. 8, 1989.
8. YAMABE, H., KOBAYASHI, K., TAKATA, T., et al.: Reduced chronotropic reserve to the metabolic requirement during exercise in advanced heart failure with old myocardial infarction. Japanese Circulation Journal, 51: 259-264, 1987.
9. BALOGUN, M. O., AJAYI, A. A. and LADIPO, G. O.: Spectrum of treadmill exercise responses in Africans with normotension, essential hypertension and hypertensive heart failure. International Journal of Cardiology, 21: 293-300, 1988.
10. DOBA, N., SHUKUYA, M., YOSHIDA, H., et al.: Physical training of the patients with coronary heart disease: noninvasive strategies for the evaluation of its effects on the oxygentransport system and myocardial ischemia. Japanese Circulation Journal, 54: 1409-1418, 1990.
11. ZDRENGHEA, D. G. N., PREDESCU, D, TIMIS, D, et al.: Exercise testing in patients with valvular disease. Romanian Journal of Internal Medicine, 32: 23-28, 1994.
12. BUSSIERES, L. M., PFLUGFELDER, P. W., MENKIS, A. H., et al.: Basis for aerobic impairment in patients after heart transplantation. Journal of Heart and Lung Transplantation, 14: 1073-1080, 1995.
13. LEGGET, M. E., KUUSISTO, J., HEALY, N. L., et al.: Gender differences in left ventricular function at rest and with exercise in asymptomatic aortic stenosis, American Heart Journal, 131: 94-100, 1996.
14. STRINGER, W. W.: Mechanisms of exercise limitation in HIV+ individuals. Medicine and Science in Sports and Exercise, 32: S412-S421, 2000.
15. HOPEWELL, P. C. and LUCE, J. M.: Pulmonary involvement in the acquired immunodeficiency syndrome. Chest, 87: 104-112, 1985.
16. STOVER, D. E., WHITE, D. A., ROMANO, P. A., et al.: Spectrum of pulmonary diseases associated with the acquired immune deficiency syndrome. American Journal of Medicine, 78: 429-437, 1985.
17. RICHMAN, D. D., FISCHL, M. A., GRIECO, M. H., et al.: The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial, New England Journal of Medicine, 317: 192-197, 1987.
18. CALABRESE, L. H., PROFFITT, M. R., YEN-LIEBERMAN, B., et al.: Congestive cardiomyopathy and illness related to the acquired immunodeficiency syndrome (AIDS) associated with isolation of retrovirus from myocardium. Annals of Internal Medicine, 107: 691-692, 1987.
19. GRODY, W. W., CHENG, L. and LEWIS, W.: Infection of the heart by the human immunodeficiency virus. American Journal of Cardiology, 66: 203-206, 1990.
20. HECHT, S. R., BERGER, M., VAN TOSH, A., et al.: Unsuspected cardiac abnormalities in the acquired immune deficiency syndrome. An echocardiographic study. Chest, 96: 805-808, 1989.
21. GRAU, J. M., MASANES, F., PEDROL, E., et al.: Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy. Annals of Neurology, 34: 206-211, 1993.
22. LANE, R. J., MCLEAN, K. A., MOSS, J., et al.: Myopathy in HIV infection: the role of zidovudine and the significance of tubuloreticular inclusions. Neuropathology and Applied Neurobiology, 19: 406-413, 1993.
23. BENBRIK, E., CHARIOT, P., BONAVAUD, S., et al.: Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. Journal of Neurological Sciences, 149: 19-25, 1997.
24. CHARIOT, P., BENBRIK, E., SCHAEFFER, A., et al.: Tubular aggregates and partial cytochrome c oxidase deficiency in skeletal muscle of patients with AIDS treated with zidovudine. Acta Neuropathology, 85: 431-436, 1993.
25. CENTERS FOR DISEASE CONTROL AND PREVENTION: Revised Surveillance Case Definition for HIV Infection. Morbidity and Mortality Weekly Report, 48(RR13): 29-31, 1999.
26. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents by a Panel on Clinical Practices for Treatment of HIV Infection. HIV Clinical Trials, 2: 227-306, 2001.
27. AMERICAN COLLEGE OF SPORTSMEDICINE: ACSM's Guidelines for Exercise Testing and Prescription. (Williams and Wilkins: Baltimore), 1991.
28. WASSERMANN, K. H. J., SUE, D. Y. and WHIPP, B. J.: Principles of Exercise Testing and Interpretation (Lea and Febiger: Philadelphia), 1994.
29. LEWIS, S. F. and HALLER, R. G.: Physiologic measurement of exercise and fatigue with special reference to chronic fatigue syndrome. Reviews of Infectious Diseases, 13: S98-S108, 1991.
30. PINA, C. R.: Lead systems: sensitivity and specificity. Cardiology Clinics, 2: 329-335, 1984.
31. NEVILL, A. M. and HOLDER, R. L.: Body mass index: a measure of fatness or leanness? British Journal of Nutrition, 73: 507-517, 1995.
32. ROSENBERG, P. S., BIGGAR, R. J. and GOEDERT, J. J.: Declining age at HIV infection in the United States. New England Journal of Medicine, 330: 789-790, 1994.
33. NEUFER, P. D., COSTILL, D. L., FLYNN, M. G., et al.: Improvements in exercise performance: effects of carbohydrate feedings and diet. Journal of Applied Physiology, 62: 983-988, 1987.
34. POOLE, D. C. and RICHARDSON, R. S.: Determinants of oxygen uptake. Implications for exercise testing. Sports Medicine, 24: 308-320, 1997.
35. VAN DER BEEK, E. J., VAN DOKKUM, W., WEDEL, M., et al.: Thiamin, riboflavin and vitamin B6: impact of restricted intake on physical performance in man. Journal of the American College of Nutrition, 13: 629-640, 1994.
36. KAUL, S., FISHBEIN, M. C. and SIEGEL, R. J.: Cardiac manifestations of acquired immune deficiency syndrome: a 1991 update. American Heart Journal, 122: 535-544, 1991.
37. LEWIS, W., PAPOIAN, T., GONZALEZ, B., et al.: Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts. Laboratory Investigation, 65: 228-236, 1991.
38. MILEI, J., GRANA, D., FERNANDEZ-ALONSO, G., et al.: Cardiac involvement in acquired immunodeficiency syndrome - a review to push action. The Committee for the Study of Cardiac Involvement in AIDS. Clinical Cardiology, 21: 465-472, 1998.
39. RERKPATTANAPIPAT, P. and WONGPRAPARUT, N., JACOBS, L. E., et al.: Cardiac manifestations of acquired immunodeficiency syndrome. Archives of Internal Medicine, 160: 602-608, 2000.
40. YUNIS, N. A. and STONE, V. E.: Cardiac manifestations of HIV/ AIDS: a review of disease spectrum and clinical management. Journal of the Acquired Immune Deficiency Syndrome and Human Retrovirology, 18: 145-154, 1998.
41. DOMANSKI, M. J., SLOAS, M. M., FOLLMANN, D. A., et al.: Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. Journal of Pediatrics, 127: 137-146, 1995.
42. MORGELLO, S., WOLFE, D., GODFREY, E., et al.: Mitochondrial abnormalities in human immunodeficiency virus-associated myopathy. Acta Neuropathology, 90: 366-74, 1995.
43. DALAKAS, M. C., PEZESHKPOUR, G. H., GRAVELL, M., et al.: Polymyositis associated with AIDS retrovirus. Journal of the American Medical Association, 256: 2381-2383, 1986.
44. CHAD, D. A., SMITH, T. W., BLUMENFELD, A., et al.: Human immunodeficiency virus (HIV)-associated myopathy: immunocytochemical identification of an HIV antigen (gp 41) in muscle macrophages, Annals of Neurology, 28: 579-582, 1990.
45. GHERARDI, R. K., FLOREA-STRAT, A., FROMONT, G., et al.: Cytokine expression in the muscle of HIV-infected patients: evidence for interleukin-1 alpha accumulation in mitochondria of AZT fibers. Annals Neurology, 36: 752-758, 1994.
46. SIMPSON, D. M., CITAK, K. A., GODFREY, E., et al.: Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished? Neurology, 43: 971-976, 1993.
47. CUPLER, E. J., LEON-MONZON, M., MILLER, J., et al.: Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain, 119: 1887-1893, 1996.
48. CHARIOT, P., MONNET, I. and GHERARDI, R.: Cytochrome c oxidase reaction improves histopathological assessment of zidovudine myopathy. Annals of Neurology, 34: 561-565, 1993.
49. MCCURDY, D. T. 3RD. and KENNEDY, J. M.: AZT decreases rat myocardial cytochrome oxidase activity and increases beta-myosin heavy chain content. Journal of Molecular and Cellular Cardiology, 30: 1979-1989, 1998.
50. DE LA ASUNCION, J. G., DEL OLMO, M. L., SASTRE, J., et al.: Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver. Hepatology, 29: 985-987, 1999.
51. SZABADOS, E., FISCHER, G. M., TOTH, K., et al.: Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat. Free Radicals in Biology and Medicine, 26: 309-317, 1999.
52. LEWIS, W., GONZALEZ, B., CHOMYN, A. and PAPOIAN, T.: Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria. Journal of Clinical Investigation, 89: 1354-1360, 1992.
53. ARNAUDO, E., DALAKAS, M., SHANSKE, S., et al.: Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet, 337: 508-510, 1991.
54. GONZALEZ, CID. M. and LARRIPA, I.: Genotoxic activity of azidothymidine (AZT) in in vitro systems. Mutation Research, 321: 113-118, 1994.
55. WEISSMAN, J. D., CONSTANTINITIS, I., HUDGINS, P., et al.: 31P magnetic resonance spectroscopy suggests impaired mitochondrial function in AZT-treated HIV-infected patients. Neurology, 42: 619-623, 1992.
56. SINNWELL T. M., SIVAKUMAR K., SOUEIDAN S., et al.: Metabolic abnormalities in skeletal muscle of patients receiving zidovudine therapy observed by 31P in vivo magnetic resonance spectroscopy. Journal of Clinical Investigation, 96: 126-131, 1995.
57. RUTENFRANZ, J., LANGE ANDERSEN, K., SELIGER, V., et al.: Maximal aerobic power affected by maturation and body growth during childhood and adolescence. European Journal of Pediatrics, 139: 106-112, 1982.
58. BEUNEN, G., BAXTER-JONES, A. D., MIRWALD, R. L., et al.: Intraindividual allometric development of aerobic power in 8- to 16-year-old boys. Medicine and Science in Sports and Exercise, 34: 503-510, 2002.